Martin George Sanda, MD

Transcription

EMORY UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE
Revised: 06/24/2013
Office Address:
1365 Clifton Road, Clinic B
Atlanta, GA 30322
Telephone:
Fax:
(404) 778-6874
(404) 778-4336
E-mail Address:
[email protected]
Citizenship:
United States of America
CURRENT TITLES AND AFFILIATIONS:
2/2013 – Present
Chairman of the Department of Urology
Emory University School of Medicine
Chief of Urology Services
Emory Healthcare
Director of the Prostate Cancer Center
Winship Cancer Institute
Woodruff Health Sciences Center
2013-present
Acting Professor of Urology, Emory University
2011-present
Professor of Surgery in Urology
Harvard Medical School
PREVIOUS ACADEMIC AND PROFESSIONAL APPOINTMENTS:
1995
Instructor/Lecturer in Urology
Johns Hopkins School of Medicine, Baltimore, MD
1995-1999
Assistant Professor of Surgery (Urology) and Oncology
University of Michigan Medical School
1999-2003
Associate Professor of Urology (with tenure) and Oncology
2004-2005
Visiting Associate Professor of Surgery
2005-2011
Associate Professor of Surgery/Urology
Page 2
PREVIOUS ADMINISTRATIVE AND/OR CLINICAL APPOINTMENTS:
1995
Attending Staff Urologist
The Johns Hopkins Hospital
1995
Assistant Chief of Service
The Johns Hopkins Hospital
1995-1998
Chief of Urology
Ann Arbor VAMC
1995-1997
Director, Ann Arbor VAMC Rotation
(University of Michigan Urology Residency; reaccreditation, 1997)
Ann Arbor VAMC
1997-2003
Attending Staff Urologist
University of Michigan Hospital
1999-2001
Director of Urology Research, Surgery Department, Urology Section
University of Michigan
1999-2003
Associate Director, Multi-disciplinary Prostate Cancer and GU
Oncology Program
University of Michigan Cancer Center
2001-2003
Associate Chair (Research), Urology Department
2001–2003
Director of Urological Oncology, Urology Department
2003
Director, O’Brien Urology Research Center
2004-2013
Director, Prostate Cancer Center
Beth Israel Deaconess Medical Center (BIDMC)
2004-2013
Founding Director, Multidisciplinary Prostate Cancer Clinic
Beth Israel Deaconess Medical Center (BIDMC)
2007-2013
Co-Director, Prostate Cancer SPORE Career Development Program
Dana Farber / Harvard Cancer Center
2009-2013
Co-Leader, Prostate Cancer Program
Dana Farber / Harvard Cancer Center
LICENSURES/BOARDS:
1987-1989
1988
1989-1995
1995-2003
Virginia License to Practice Medicine
Diplomate, National Board of Medical Examiners
Maryland License to Practice Medicine
Michigan License to Practice Medicine
2003
Page 3
Certification, Robot-Assisted Laparoscopic Prostatectomy (recertified
in 2008)
Massachusetts License to Practice Medicine
Fundamentals of Laparoscopic Surgery Certification, SAGES
Georgia License to Practice Medicine
2003-present
2009
2013
SPECIALTY BOARDS:
1997-present
Board Certified: American Board of Urology (recertified in 2007)
EDUCATION:
1983 BA
cum laude
Molecular Biophysics and Biochemistry
Yale University, New Haven, CT
1987
Medicine
Columbia University College of Physicians and Surgeons, NY, NY
MD
POSTGRADUATE TRAINING:
1987-1989
Resident (PGY I-II)
General Surgery
Medical College of Virginia, Richmond, VA
1989-1991
Fellow
Surgical Oncology & Immunology
National Cancer Institute, National Institute of Health, Bethesda, MD
1991-1995
Resident (PGYIII-VI)
Urology
Johns Hopkins Hospital, Baltimore, MD
COMMITTEE MEMBERSHIPS
a. National and International:
National Institutes of Health:
1998-2004
American College of Surgeons Oncology Group GenitoUrinary Committee
Committee member
2000-2006
Radiation Therapy Oncology Group (RTOG) GenitoUrinary Cancer Steering Committee
Committee member
2001-2004
ACOSOG (American College of Surgeons Oncology
Group) Protocol Z0071: HRQOL Companion Study for
the SPIRIT Trial - National Cancer Institute
Committee Chair
2001-2005
RTOG Outcomes Steering Committee
Committee member
2002-present
RTOG (Radiation Therapy Oncology Group)
Protocol P-0232
National Cancer Institute
Urology co-Chair
Page 4
2004present
Eastern Cooperative Oncology Group Genito-Urinary
Committee Prostate Cancer Conservative Management
Trial Concept Chair (ECOG 7802); Group co-Chair,
START Phase III Trial
Committee member;
Leader, GU Early
Modalities Working
Group (2007-2009)
2005-present
NCI – Early Detection Research Network (EDRN)
Steering Committee
Committee member;
Leader, Prostate
Reference Set
2005-2006
NCI-EDRN GU Collaborative Group
Group member
2007-2010
NCI-EDRN Executive Committee
Committee member
2007-2010
Prostate & Genito-Urinary Cancers Collaborative Group,
Early Detection Research Network
Committee Chair
2007-2010
2008
2009
2010
Leader/moderator, monthly group
conference calls
Leader/Moderator, GU Collaborative Group
Meeting at the 17th Bi-Annual EDRN
Steering Committee Meeting, March 2008
Meeting; 5th Annual EDRN Scientific
Workshop, Bethesda, MD September, 2008
Meeting; 18th Bi-Annual EDRN Steering
Committee Meeting, Houston, TX,
March 2009
GU Collaborative Group Leader, 6th Annual
EDRN Scientific Workshop, Bethesda, MD
August 2009
Meeting, 20th Bi-Annual EDRN Steering
Committee Meeting, Tempe, AZ,
March 2010
2007-2012
ECOG Genito-Urinary Committee: GU Early Modalities
Working Group
Group Leader
2010
NCI Inter-SPORE Prostate Cancer Active Surveillance
Working Group
Working Group coLeader
2011-present
USA Region, Prostate Cancer Urinary Biomarkers Global
Advisory Panel
Movember
Member
2011-present
AUA Research Council
American Urological Association
Representative of the
New England Section
2012-present
USA Region, Early Disease Survivorship Initiatives
Movember and Prostate Cancer Foundation
Page 5
Advisor
Department of Defense:
2006-2007
Prostate Cancer Research Program Vision/Strategic
Steering Committee
Full Committee member
Grant Review Activities:
National Institutes of Health:
1996
Special Review Committee: GCRC Site Visit Team,
University of Tennessee
Committee member
1996
Special Review Committee for RFA CA-95-021 (GI
Cancer SPOREs)
Committee member
1997
Special Review Committee for NIDDK RFA DK-97-008
(Prostatitis Collaborative Clinical Studies)
Committee member
1998
Special Review Committee for NIDDK ZDK GRB-7
(Urology O’Brien Center Applications)
Committee member
1999
Special Review Site Visit Committee, PO1 CA81402
Committee member
2000
Special Review Committee for NCI-SPORE Proposals
Committee member
2003
Site Visit and Review Committee: Duke University
Program Project Grant
Ad-hoc Committee
member
2006, 2011
Prostate SPORE Applications Review Committee
Committee member
Department of Defense:
1999
Prostate Cancer Research Program Application Review
Committee
Committee member
2003
Prostate Cancer Research Program Integration Panel
Committee member- ad
hoc
2006-2007
Prostate Cancer Research Program Integration Panel
and Strategic Planning Committee
Permanent Panel
Member
Prostate Cancer Foundation
2010-2012
PCF New Investigator Awards
Review Panel Member
2011
PCF Idea and Challenge Awards
Review Panel Member
Page 6
b. Regional and State:
1998-2003
North Central Section - AUA
Member
2008-present
New England Section – AUA
Member
c. Institutional:
University of Michigan School of Medicine, Ann Arbor, MI:
1998-2003
Prostate Cancer SPORE Center Executive Committee
Committee member
1999-2003
Robert Wood Johnson Clinical Scholars Program
Scholar candidate
interviews
2001-2003
PIBS Graduate Program
Candidate interviews
Ann Arbor VAMC:
1995-1997
Tumor Board
Committee member
University of Michigan Hospital:
1997-2003
UM-Urology Prostate Cancer Care Quality Assurance
(outcomes database working group)
Directed QA group,
1997-2000; member,
2001-2003
1998-2001
General Clinical Research Center Protocol Review
Committee
Ad-hoc Reviewer
2002-2003
Bed Utilization Committee
Committee member
Harvard Medical School, Boston, MA:
2004
John Warren Surgical Society
Roundtable Discussant
2005 – 2013
Harvard Cancer Center Prostate SPORE
Executive/Governance Committee
Committee member
2006
Cancer Survivorship Conference Planning Committee
Committee member
2006–2007;
2010
Harvard-Longwood Urology Residency Applicant Review/
Selection Committee
Committee member
2007–2013
Harvard Prostate SPORE Developmental and Career
Development Award Proposal Review Committee
Committee member
2008
ICER Early Stage Prostate Ca External Radiotherapy
Evidence Review Group, MGH Institute for Technology
Assessment/ Clinical & Economic Review
Committee member
Page 7
2009
ICER Active Surveillance and Radical Prostatectomy
Evidence Review Group, MGH Institute for Technology
Assessment/ Clinical & Economic Review
Committee member
2009-2013
Dana Farber/Harvard Cancer Center Scientific Council
Committee member
2012
Professorial Search Committee for the Professor and
Director of Men’s Health, Department of Medicine,
Brigham-Women’s Hospital
Committee member
Beth Israel Deaconess Medical Center:
2004
Surgery Department Quality Improvement Committee
Committee member
2005-2006
Prostate Care Center Ad Campaign Working Group
Program Leader
2005-2013
BIDMC Cancer Registry Committee (M Houlihan,
Committee Chair)
Committee
Member/Prostate
Cancer Representative
2005-2013
Prostate Cancer – Hershey Tissue Bank Committee
Committee member
2006-2007
BIDMC Cancer Center of Excellence Capital Campaign
Planning Group
Co-Leader
2007- 2008
Surgery Department Resident Research Competition
Review Panel
Committee member
2008
OR RAC Business Plan for Robot-Assisted
Prostatectomy (co-developed with Dr. Andrew Wagner)
Ad Hoc
2008
Radiation Oncology Faculty Search Committee:
Recruitment of Junior Faculty to Focus on Prostate
Radiotherapy
Committee member
2009
OR Credentialing Committee: Subcommittee Working
Group for Davinci Robot Credentialing Guidelines
Ad Hoc
2009
Cancer Care Measures Working Group
Working group member
2009
Pathology Faculty Search Committee: Recruitment of
Molecular Pathologist with GU Pathology Expertise
Committee member
2009
Cancer Web Advisory Group
Group member
2009
Surgery Department Strategic Urology Refresh Working
Group
Working group member
2009
BIDMC Marketing: Prostate Center Google Ad Campaign
Working Group: Assisted J Lyons & J Siegal in Prostate
Center BIDMC 2009 Google Ad campaign
Ad Hoc
Page 8
2009
BIDMC Public Relations: Prostate Health Month on
bostonchannel.com: Co-led working group with Rhonda
Mann and Heather Maloney
Ad Hoc
2009-2013
BIDMC Inter-Departmental Prostate Cancer Program
Executive Committee (PEC)
Committee Activities:
Quarterly Committee Meetings
Fund Raising Events / Hosting:
Prostate Cancer Foundation Site Visit
Manzanilla Family Site Visit
Prostate Cancer Supporters’ Update Breakfast
BIDMC Cancer Advisory Board
Prostate Cancer Supporters’ Update Breakfast
New Investigator Award Selection Panel
Program Presentation for External Advisory Board
Site Visit and Program Review
Prostate Cancer Advisory Board Inaugural Meeting
Committee Chair
BIDMC Cancer Clinical Trials Oversight Committee
Committee member
2010-2013
EDITORSHIPS AND EDITORIAL BOARDS:
2010-present
Editorial Board, The Prostate (Impact Factor = 3.67)
MANUSCRIPT REVIEWER:
Ad Hoc Reviewer:
JAMA
Lancet Oncology
Journal of Clinical Oncology
Cancer Research
Journal of Clinical Investigation
Clinical Cancer Research
The Prostate
Journal of Urology
Urology
British Journal of Urology
2009-2013
July 2009
August 2009
October 2009
October 2010
October 2010
2009-2010
October 2010
October 2011
Page 9
HONORS AND AWARDS:
Year
Name of Honor/Prize
Awarding Organization
Type of Award
1987
Sandoz Award for Excellence in Medical
Research: “IL-2 Inhibition by a Gly-Pro Affinity
Column Eluate”
Columbia University
College of Physicians &
Surgeons
Research
Excellence
1993
Basic Science Research Prize, Second Place.
“Human Prostate Cancer Cells are Suitable
Targets for Gene-Modified Immunotherapy”
American Urological
Association
Research
Excellence
1994
CaPCure Award, Second Place. “Gene Therapy
for Human Prostate Cancer”
American Urological
Association
Research
Excellence
1994
Clinical Research Prize Second Place. “Genetic
Susceptibility of Benign Prostatic Hyperplasia”
American Urological
Association
Research
Excellence
1998
European Association of Urology Traveling
Fellowship
American Urological
Association
Scholarly
Accomplishments
1998
Pfizer Scholars in Urology Award
American Foundation of
Urological Disease
Scholarly
Accomplishments
1999
Society for Basic Urologic Research Young
Investigator Award
Society for Basic
Urologic Research
Research
Excellence
2001
Outstanding Achievement Award
Urology Residents
Teaching
2003 2012
Best Doctors in America: Best in Michigan
(2003-4); Best in Massachusetts (2005-12)
Castle-Connolly:
National peer survey
Clinical Care
2005
Society of Urological Oncology Young
Investigator Award
Society of Urological
Oncology
Scholarly
Accomplishments
20052012
Best of Boston - Top Doctors (Urology)
Boston Magazine
Clinical Care
2010
Visiting Professor, Urology
Division of Urology,
University of Chicago
Scholarly
Accomplishments
2010
Leadership Development for Physicians at
Academic Health Centers (Select Course at
Harvard School of Public Health)
Nominated by Senior
Leadership at BIDMC
Administration
2010
Service Recognition Award for 3-year term as
Chair, EDRN Prostate/GU Collaborative Group
Administrative
Leadership
2011
Honorary Degree: Master of Arts
Harvard University
Scholarly
Accomplishments
Page 10
2012
Visiting Professor
Memorial Sloan
Kettering Cancer Center
Scholarly
Accomplishments
2012
J. Hartwell Harrison Memorial Resident Education
Award
Harvard-Longwood
Urology Residency
Teaching
SOCIETY MEMBERSHIPS:
1995-present
American Urological Association (AUA)
Member
1999-2003
Abstract Review Committee
Committee member
2001-2004
Research Priorities Committee
Committee member
2004
Prostatectomy Outcomes Blue Ribbon Panel
Committee member
2006-2007
ASCO/AUA Cancer Quality Committee
Committee member
2008
AUA Annual Meeting Podium Presentations:
Prostate Cancer Staging II
Session Moderator
2008
PSA Guidelines Review Committee
Clinical Guidelines
Reviewer
2008-2009
Stereotactic Radiosurgery Task Force
Committee member
2009
New England Section Meeting: Podium
Presentations, Prostate Cancer
Session Moderator
AUA National Meeting: Prostate Cancer
Research Poster Session
Session Moderator
AUA Annual Meeting – AUA Foundation Forum:
“Showcasing Young Investigators”
Review Panel Member
AUA Foundation Scholars Career Mentoring
Program
Designated Program
Mentor
1997-present
Reed Nesbit Society
Member
1999-present
Society of Urological Oncology
Member
2006
Annual AUA-SUO Meeting Program Committee
Committee member
2010
Prostate Cancer Committee
Committee Member
2010
Abstract Review Committee
Abstract Reviewer
2010
Annual Meeting Program Committee – Prostate
Cancer Session
Moderator, Prostate
Cancer Session I:
Intermediate Risk
2010
2010
2010
Page 11
2000-2009
American Association of Immunologists
Member
2000-present
American Society of Clinical Oncology
Member
2012
Education Committee
Committee Member
ORGANIZATION OF NATIONAL OR INTERNATIONAL CONFERENCES:
a. Administrative positions:
2006-2007
Director, Annual Course in Urological Complications
American Urological
Association Annual
Meeting
2007-2012
ECOG Genito-Urinary Committee:
Leader, GU Early Modalities Working Group
2011-present
Leader, USA Region, Prostate Cancer Urinary Biomarkers
Global Advisory Panel
Movember
2011-13
AUA Research Council – Representative to the AUA of the
New England Section
American Urological
Association
2012-present
Advisor, USA Region, Early Disease Survivorship
Initiatives
Movember and Prostate
Cancer Foundation
b. Sessions as chair:
2001-2004
Chair, ACOSOG (American College of Surgeons
Oncology Group) Protocol Z0071: HRQOL Companion
Study for the SPIRIT Trial
2002-present
Urology co-Chair, RTOG (Radiation Therapy Oncology
Group) Protocol P-0232
2007-2010
Chair, Prostate & Genito-Urinary Cancers Collaborative
Group, Early Detection Research Network
2007-2010
2008
2009
2010
Leader/moderator, monthly group conference calls
Leader/Moderator, GU Collaborative Group Meeting at the 17th BiAnnual EDRN Steering Committee Meeting, March 2008
Leader/Moderator, GU Collaborative Group Meeting; 5th Annual EDRN
Scientific Workshop, Bethesda, MD September, 2008
Leader/Moderator, GU Collaborative Group Meeting; 18th Bi-Annual
EDRN Steering Committee Meeting, Houston, TX, March 2009
GU Collaborative Group Leader, 6th Annual EDRN Scientific Workshop,
Bethesda, MD August 2009
Leader/Moderator, GU Collaborative Group Meeting, 20th Bi-Annual
EDRN Steering Committee Meeting, Tempe, AZ, March 2010
Page 12
RESEARCH FOCUS:
I established a prostate cancer immunology laboratory as PI in 1996 and have held continuous NIH
funding since then. The scope of my prostate cancer research expanded to evaluating prostate
cancer antigens as markers for early detection and to investigating patient-reported outcomes
among prostate cancer survivors.
PATENTS:
a. Pending:
Method and composition for prostate cancer immunotherapy
US Patent Application, filed May 1 2008 (USSN: 61/126,065)
This patent covers novel immunogenic epitopes from two prostate cancer antigens for prostate
cancer immunotherapy. These epitopes can be used in vaccine formulation to trigger immunity
against prostate tumors in humans. I developed the strategy for identifying the target prostate cancer
antigens and their epitopes and together with Mohammed Arredouani, Ph.D., an Instructor in my
laboratory, we designed and supervised the experiments that showed immunogenicity of these
epitopes in humanized transgenic mice. We are seeking industry partners to bring these antigens to
Phase I clinical trial.
GRANT SUPPORT:
a. Active Support:
I.
Federally Funded
Years
Sponsor
PI / Role
2005-2015
NIH
PI: M. Sanda
Harvard/Michigan/Cornell
U01 2U01CA113913
Prostate Cancer
($2,522,603 Direct
Biomarker Clinical
Cost for current
Validation Center
funding cycle,
2010-15)
The major goal is to evaluate and validate new biomarkers for detecting
prostate cancer
2012-2017
NIH
R01NR009692
($175,000 to Sanda
Team / BIDMC;
subcontract to Emory
pending)
National PI: D. Berry
BIDMC Site PI (2012-3):
Sanda
Emory Site PI (pending
transfer): Sanda
Grant Title
Personal Patient ProfileProstate: A Randomized
Multi-site Trial
Page 13
II. Other/Current Funded Research
Years
Sponsor
PI / Role
Grant Title
2012-2014
American Urological
Association
PI: M Sanda (Mentor, AUA
Scholarship; AUA Scholar:
Peter Chang, M.D.)
2011-2013
Prostate Cancer
Foundation Challenge
$1,000,000 Direct
Cost
Consortium PI: M. Sanda
(Site PI’s: Hopkins – Drake;
North Carolina – Desimone;
BIDMC - Arredouani
Measuring PatientReported Prostate Cancer
Outcomes at the Point of
Care
The goal is to implement using prostate cancer PRO measures at the point of
routine care
Nanoparticle-Targeted
Peptide Vaccines for
Prostate Cancer:
The Harvard – Hopkins –
Carolina Consortium
The major goal is to optimize peptide vaccine delivery by nanoparticle adjuvants to
enable subsequent clinical trial
Project
Role
Radiation Therapy Oncology Group (RTOG) Trial 0232: A phase III
study comparing combined external beam radiation and transperineal
interstitial permanent brachytherapy with brachytherapy alone for
patients with intermediate risk prostate cancer. (Open trial accruing
subjects)
Protocol co-Chair
(Urology)
b. Previous Support
Years
Sponsor
PI / Role
Grant Title
1995
NIH / P50CA 69568
Prostate Cancer
SPORE Developmental Award
Center PI: K. Pienta
Project PI: M. Sanda
Effects of Prostate-Specific Bclx-s
Trans-gene Expression on Prostatic
Carcinogenesis
1996
NIH: P50CA69568
Developmental
Student Award
Program PI: K. Pienta
Project PI: Med Student
Fellow: C. Hwang
Prostate-specific Expression of PSA
in Transgenic Mice with Prostate
Cancer
1996-1997
U Michigan Cancer
Center Developmental Award
(Pilot funds from NIH
P30 CA46592)
Center PI: M. Wicha
Intravesical Adenovirus Therapy of
Human Transitional Cell Carcinoma
Orthotopic Xenografts in nu/nu Rats
1996-1999
American Cancer
Society - Clinical
Career Development
Award 96-77
PI: M. Sanda
Prostate Cancer Prevention and Gene
Therapy with Recombinant Vaccines
(PI Stipend)
Page 14
1996-2000
NIH R29 CA71532
PI: M. Sanda
Prostate Cancer Gene Therapy with
Recombinant Vaccines.
1997
CaPCURE
Foundation
(For Sanda Lab
Equipment)
PI: M. Sanda
A Phase I Trial Evaluating VacciniaPSA Vaccine in Patients with PSA
Recurrence of Prostate Cancer
Following Radical Prostatectomy
1997-1998
NIH: P50CA 69568
PI: K. Pienta
Sanda role: CoInvestigator
Prostate Cancer SPORE Animal and
Tissue Core
1997-1998
Howard Hughes
Medical Institute
Medical Student
Fellowship
Medical Student Fellow:
C. Hwang
Immunological Tolerance to an
Inducible, Tumor Associated Antigen
Expressed in Normal and Malignant
Prostatic Epithelium
1998-1999
Robert Wood
Johnson Scholars
Program Mentor
Postdoctoral Scholar: J.
Wei Sanda role:
co-Mentor (with J Montie)
RWJ Scholars Program Mentor
1998-2002
NIH
P50-CA69568
Sanda lab Project 6
Program PI: K Pienta
Sanda role:
Director, Project 6
Phase II Trial of Vaccinia-PSA in
Prostate Cancer Recurrence after
Radical Prostatectomy
1998-2003
NIH
P01CA75136-01A1
Sanda lab Project #4
PI: M. Clarke
Sanda role:
Director, Project 4
P01: Targeting PCD for Cancer
Therapy. Project 4: Targeting
Programmed Cell Death in Bladder
Cancer Gene Therapy
1999-2000
Department of
Surgery
PI: M. Sanda
Effects of localized prostate cancer
intervention and progression on
health-related quality of life
1999-2001
NIH R29 CA71532
Supplement
PI: M. Sanda
Validation of Mouse Models of Cancer
2000-2005
NIH
R01 CA8241901-A1
PI: M. Sanda
Modulating tolerance for prostate
cancer antigen vaccines.
2001-2003
NIH
P30 CA46592
Center PI: M. Wicha
Sanda role: Associate
Director, Prostate Cancer
& Urologic Oncology
Program
Comprehensive Cancer Center
2001-2004
U Michigan Cancer
Innovation Grant
(Pilot funds from NIH
P30 CA46592)
PI: M. Sanda
Measuring quality of cancer care:
Validation of a patient-reported
multidimensional satisfaction
instrument
Page 15
2002-2009
NIH
R01 CA95662
PI: M. Sanda
Survivor QOL and spouse satisfaction
after prostate therapy
2003
NIH
P50 CA69568-02A1
SPORE PI: K Pienta
Sanda role:
Developmental Award
Core Director
UM Prostate Cancer SPORE
(Developmental Award Core).
2003
NIH
P50 CA69568-02A1
SPORE PI: K Pienta
Project 6 Director: D
Robins. Sanda role:
Project 6 co-Investigator
UM Prostate Cancer SPORE
(Project 6)
2003-2008
NIH
P50CA69568-02A1
SPORE PI: K Pienta
Project 3 Director: A.
Chinnayian
Sanda role: CoInvestigator
UM Cancer Center Prostate Cancer
SPORE Project 3
2003-2008
NIH
P50 DK065313
PI: M. Sanda, 2003-2004;
M Day assumed PI role in
2004 due to Sanda’s
move to BIDMC; Sanda
then continued as Proj 3
Director
O’Brien Urology Research Center
2005-2010
NIH (NCI EDRN)
1U01CA113913
PI: M. Sanda
Harvard/Michigan Prostate Cancer
Biomarker Clinical Center
2006-2009
Lance Armstrong
Foundation
PI: J Hu, M.D., MPH
Sanda role: co-Mentor
New Investigator Award: Minimally
Invasive Prostatectomy.
2007-2012
NIH-NCI
P50 Prostate Cancer
SPORE
2008-2011
Prostate Cancer
Foundation Young
Investigator Award
PI: M. Arredouani, Ph.D.
Sanda role: Mentor
Novel tumor-associated antigens and
strategies for prostate cancer
immunotherapy
2009-2010
Harvard Catalyst
Project
Proteomic discovery of prostate
cancer biomarkers
2009-2011
Department of
Defense Postdoctoral
Fellowship Award
PI: T. Libermann, Ph.D.
Sanda role: coInvestigator
PI: B. Lu, Ph.D.
Sanda role: Mentor
PI: P. Kantoff, M.D.
Dana Farber/Harvard Cancer
Sanda role: co-Director,
Center Prostate SPORE:
Career Development
Career Development Award
Award Program
Program
The career development program objective is to identify and mentor new
investigators in prostate cancer translational research investigators at HMSaffiliated institutions.
Sim2, a Putative Prostate Cancer
Tumor Antigen
Page 16
2009-2012
Department of
PI: S. Balk, M.D., Ph.D.
Invariant NKT Cell Ligands for
Defense Prostate
Sanda role: coProstate Cancer Vaccines
Cancer Clinical
Investigator (10% FTE),
Translation Award
co-Director of Project 2
The major goal is to develop avenues for bringing NKT immunotherapy to clinical
trial
2009-2012
Department of
PI: M. Arredouani, Ph.D.
Targeting Tim-1 to Circumvent
Defense New
Sanda role: Mentor
Immune Tolerance in Prostate
Investigator Award
Cancer
The major goal is to augment prostate cancer vaccine efficacy by disrupting
regulatory T cell function
2009-2012
NIH
PI: M. Sanda
Effectiveness of Robotic Compared to
1RC1EB011001
Standard Prostatectomy for Prostate
$710,318 Direct Cost
Ca
The objective is to compare treatment efficacy, morbidity, and cost of robotassisted to open prostatectomy
2009-2012
NIH
1RC1CA146596
$801,190 Direct Cost
PI: M. Sanda
Effectiveness of Early
(Multiple PI/PD Proposal
Stage Prostate Cancer
together with P. Carroll,
Treatment
UCSF; Sanda is contact
PI)
The overall goal is to build comparative effectiveness models for different
prostate cancer therapies that use baseline HRQOL to facilitate treatment
decisions
2009 -2013
NIH EDRN Clinical
BIDMC Site PI: M. Sanda
PCA3 Validation Trial and
Trial Procurement
(also member of Trial
Urinary Reference Set
Services Agreement
Leadership Group)
$86,010 Direct Cost
National PI: J Wei
The main objective is to determine whether urinary PCA3 is an effective urinary
marker to predict presence of prostate cancer
CLINICAL AND COMMUNITY SERVICE CONTRIBUTIONS:
Outcomes-Focused Clinical Care:
1995-1997
As Chief of Urology at the Ann Arbor VAMC, I expanded the clinical practice by
spearheading new faculty recruitment and restructuring clinical operations of the
service.
1997-2003
Moved my clinical practice from the Ann Arbor VAMC to the private, hospital-based
clinic setting of the University of Michigan Health System Urology Department, my
clinical practice became fully focused on urological oncology concerns with emphasis
on prostate cancer.
2004-2013
Recruited to BIDMC to lead an interdepartmental prostate cancer clinical service and
research program.
Page 17
Patient load
1995-1997
1997-2003
2004-2013
Chief of Urology at the Ann Arbor VAMC: Performed approximately 100 major
urological operations and supervised more than approximately 2000 residentassisted patient encounters.
University of Michigan Cancer Center and Department of Urology: Performed over
1000 urological operations and procedures and more than 5000 outpatient
encounters.
BIDMC: Expanded my expertise to include laparoscopic prostatectomy and robotassisted laparoscopic prostatectomy with1100 outpatient visits per year, nearly 100
inpatient admissions per year, and over 100 major urological procedures per year.
b) Clinical Innovations
• Established Multi-Disciplinary Prostate Cancer Clinic at BIDMC
• Improving Prostate Cancer Care Efficiency: Discharge 24 hours post-prostatectomy
• Greenlight laser vaporization of the prostate at BIDMC
• Introduction of Robot-Assisted Prostatectomy to BIDMC
• Robot-Assisted Cystectomy Program at BIDMC
FORMAL TEACHING:
a. Medical Student Teaching
Years
Name of Course or
Presentation
Teaching
Role
Type of Students and
# per year (N)
Time
Assistant
Chief of
Service
Medical Students (M3-M4)
N=10 in 6 months
26 hours
per year
Johns Hopkins School of Medicine
1995
Urology Elective Clinical
Rotation
1995 – 2003
Urology Elective
Clerkship
Attending
N=20/yr
20 hours
per year
1998 – 2001
Career Seminar Series:
Urology
Lecturer
N=80/yr
2 hours
per year
1998 – 2003
Clinical Skills – GU
Physical Exam
Lecturer
Medical Students (M-2)
N=12/yr
5 hours
per year
2000 - 2003
Biology 300: Independent
Research
Faculty
Mentor
Undergraduate Students
N=2/yr
30 hours
per year
2002 - 2003
Immunology 850: Tumor
Immunology
Page 18
Lecturer
Graduate Students-Program
in Biological Sciences
N=16/yr
6 hours
per year
2004-13
Surgery Core Clerkship:
Urology Rotation
Attending
Medical Students (M3)
N=20/yr
20 hours
per year
2005
Harvard/MIT Health
Sciences Technology
Program: UROP
Faculty
Supervisor
Undergraduate Students
10 hours
per month
Jan-April
2006
“Development of Prostate
Cancer Biomarkers”
Harvard School of Public
Health Course, EPI 294
Lecturer
Predoctoral students,
Harvard School of Public
Health
4 hours
2007
Introduction to Surgery
Attending
4 hours
2008
4th Year Comprehensive
Exam: Abdominal Pain
Examiner
4 hours
2008-9
Introduction to Physical
Exam:
DRE and GU Exam
Preceptor
4 hours
2011
3rd year Surgery
Clerkship Exam
Examiner
4 hours
b. Graduate Program
Years
Name of Course or
Presentation
Teaching
Role
Type of Students and
number per year
Time
1995-2003
Urology Residency
Program
Clinical
Service
Attending
Urology residents, direct
contact for clinical/operative
teaching with 15 per year
10 hours
per week
1995-2003
Univ of Michigan
Urology Journal Club
Instructor
Urology Residents
4 hours
per year
1997-2000
Univ of Michigan
Multidisciplinary GenitoUrinary Oncology
Director of
Lecture
Series
Residents, post-doctoral
fellows and faculty (Urology,
Medicine, and Radiation
Oncology)
2 hours
per week
2000-2003
Univ of Michigan
Urology Research
Summer Course:
Lecturer
Urology medical students,
residents, post-doctoral fellows
and faculty
5 hours
per year
Page 19
Fundamentals of
Urology Study Design
2009
General Surgery
Didactic Core
Curriculum: Prostate
Cancer Detection and
Management
Lecturer
General Surgery Residents
and Harvard Medical Students
2 hours
2009
Internal Medicine Core
curriculum: Kurland Firm
Conference @ BIDMC
Urology
Discussant
Internal Medicine Residents
and Harvard Medical Students
1.5 hour
c. National Post-Graduate
2006-2007
Director, Annual Course in Urological Complications
American Urological Association Annual Meeting
SUPERVISORY TEACHING:
Years
Description of Responsibilities
Time
1995 - 1997
Ambulatory Urology Clinic, Preceptor / Ann Arbor VAMC Supervised /
taught Urology residents and medical students rotating in Urology
rotation in outpatient urology clinic
One
session
per week
1995 - 1997
Urology Surgical Staff Attending / Ann Arbor VAMC
Supervised Urology residents in operating room, peri-operative inpatient
care
One
session
per week
1997 - 2003
Multidisciplinary Urological Oncology Clinic, Preceptor / University of
Michigan Comprehensive Cancer Center
Supervised & taught Urology residents, Oncology Fellows and medical
students in outpatient urological oncology clinic
One
session
per week
1997 - 2003
Inpatient OR Urology Surgical Staff Attending / University of Michigan
Hospital: Supervised & taught Urology residents in operating room, and
peri-operative inpatient care
Two
sessions
per week
2004 - 2005
Resident Urology Clinic Preceptor / Beth Israel Deaconess Medical
Center: Supervised & taught Urology residents, and medical students in
ambulatory urology clinic
One
session
per month
2004-13
Multidisciplinary Prostate Cancer Clinic Preceptor / Beth Israel
Deaconess Medical Center:
Supervised & taught Urology residents, and Radiation Oncology
residents in outpatient prostate cancer clinic
One
session
per week
2004-13
Inpatient OR Urology Surgical Staff Attending / BIDMC
Supervised & taught Urology residents in operating room, and perioperative inpatient care
One
session
per week
Page 20
2004-13
Cystoscopy Suite Urology Surgical Staff Attending / BIDMC:
Supervised & taught Urology residents in cystoscopic/endoscopic
outpatients procedures
One
session
per week
2006-13
Resident Urology Clinic Preceptor / Beth Israel Deaconess Medical
Center: Supervised & taught Urology residents, and medical students in
ambulatory urology clinic
Three
sessions
per year
a. Laboratory and Other Research Supervisory and Training Responsibilities
Years
Description of Responsibilities
Time
1995 –
present
Lab & Clinical Research: Principal Investigator, laboratory conducting
urological cancer translational/clinical research. Supervised
undergraduate& graduate students, and postdoctoral fellows
conducting clinical outcomes studies and preclinical tumor
immunology research in prostate cancer and bladder cancer.
Supervision
and
mentorship 2
days per
week
1998-2003
Established the Urology Research Advisory Committee that solicited
and critiqued pilot research proposals from fellows
2000 - 2003
Established, organized and moderated Annual Urology Department
Research Retreats, a forum for summarizing ongoing research
projects & progress. Managed an endowment-supported research
clinical infrastructure core of 5 research staff used by all Urology
faculty members.
Two days
per year
2001 - 2002
Thesis Committee member for Zheng Fu (Ph.D. candidate in
Immunobiology Track, University of Michigan Graduate Program in
Biomedical Sciences)
6 hours over
18 months
b. Formally Supervised Trainees
See Teaching Portfolio - overall summary as follows:
Predoctoral: 19 trainees
Postdoctoral: 18 trainees
Page 21
c. Formal Teaching of Peers (Continuing education medical courses)
Those presentations below sponsored by outside entities are noted and sponsor(s) are identified:
LECTURESHIPS, SEMINAR INVITATIONS, AND VISITING PROFESSORSHIPS (ONLY LAST 5
YEARS LISTED)
Year
Title/ of Presentation
Department / Institution
2008
“BIDMC Prostate Care Center: Status Report” BIDMC Cancer Executive Committee
Meeting
“Collaborative Interaction between Labaer/Anderson BDL and Sanda Prostate Cancer
CEVC: Autoantibodies against Prostate Cancer Antigens”
NCI Site Visit, Harvard Institute of Proteomics, Cambridge, MA
“Enhancing Prostate Cancer Survival and Quality of Life” Inaugural Beth Israel
Deaconess Cancer Center Symposium: Defining New Frontiers to Eradicate Cancer
“New Strategies to Detect Prostate Cancer and Predict Treatment Outcomes”
Brigham-Longwood Urology Countway Conference at BIDMC
2009
“The Prostate Center at BIDMC: Transforming Prostate Cancer Detection, Treatment,
and Outcomes” Prostate Cancer Outreach Breakfast, Harvard Club, Boston, MA
2010
"Patient-Reported Outcomes as a Measure of Cancer Care Quality"
Brown Bag Seminar, Department of Health Care Policy, Harvard Medical School
“Controversies in Early Stage Prostate Cancer Detection and Treatment”
Hematology/Oncology Grand Rounds, BIDMC
“New Paradigms for Prostate Cancer Screening” Countway Urology Rounds,
Harvard-Longwood Urology Residency
“New Molecular Targets for Prostate Cancer Early Detection” 3rd Annual BIDMC
Cancer Symposium
2011
“PSA and Prostate Cancer” The Men’s Health Forum, Harvard Medical School,
Boston, MA
2012
“Targeting Cancer-specific RNA in Urine for Prostate Cancer Detection” Countway
Urology Grand Rounds, Harvard/Longwood Program in Urology, Boston, MA
Page 22
INVITATIONS TO NATIONAL OR INTERNATIONAL CONFERENCES (ONLY LAST 5 YEARS
LISTED):
Regional Presentations
Years
Presentation
Name of host organization
2008
“Prostate Cancer HRQOL Outcomes
to Facilitate Patient Counseling
and Treatment Decisions”
Plenary Speaker, Annual Meeting,
New England Section of the AUA,
San Juan, Puerto Rico
2009
“To Treat or Not to Treat: Discerning the Duds
from the Time Bombs”
12th Annual Mass. Prostate Cancer
Coalition Symposium, Boston, MA
“Not Treating Prostate Cancer Could Be a
Good Choice”
WBUR 90.9 FM News Focus and
Podcast 8-31-09, Boston, MA
Plenary Keynote Panel: “What’s New in
Prostate Cancer?”
13th Annual Massachusetts Prostate
Cancer Symposium, Quincy, MA
“Prostate Cancer Outcomes Assessment and
Quality of Life”
15th Biennial Harvard Urologic Cancer
Course, Boston, MA
Plenary Session: “Point-Counterpoint - Active
Surveillance for Prostate Cancer”
Annual Meeting, New England Section of
the AUA, Providence, RI
“Refining Early Detection and Predicting
Outcomes of Primary Treatment”
Society of Translational Oncology
Prostate Cancer Symposium, Boston,
MA
2010
2011
National Presentations
Year
Presentation
2008
Side Effects of Primary Treatment in the
Elderly Male: Results from the PROSTQA
Consortium
Annual ASCO Genitourinary Oncology
Conference, San Francisco, CA
2009
“Disparities in Quality of Life after Prostate
Cancer Treatment”
AACR Conference on Health Care
Disparities, AZ
“Opportunities and Resources for Biomarker
Discovery”
NCI – inter-SPORE Prostate Cancer
Symposium, Baltimore, MD
“PCA3 Phase II Trial in the Context of Prostate
Biomarker Development by EDRN”
NCI PCA3 Trial Investigators’ Study
Initiation Meeting, Ann Arbor, MI
2010
2011
2012
Page 23
“The Watchful-Wait Approach to Prostate
Cancer Revisited”
“Talk of the Nation - Science Friday” Live
Interview, National Public Radio
“EDRN Resources for Prostate Cancer
Investigators”
Multi-center Prostate Cancer Retreat, Ft.
Lauderdale, FL
“Molecular Targets for Prostate Cancer Early
Detection and Immunotherapy”
Surgery Seminar Series,
University of Chicago Medical Center
“Emerging Paradigms in Prostate Cancer
Detection, Care, and Outcome”
Urology Grand Rounds,
University of Chicago Medical Center
“Management of Intermediate Risk Prostate
Cancer”
Society of Urological Oncology Annual
Meeting, Bethesda, MD
“Comparison of open, robotic, and
laparoscopic prostatectomy”
International Prostate Cancer
Symposium, New York, NY
Measuring Side Effects with Validated QOL
Instruments: Meaningful Use at the Point of
Care
Prostate Cancer: Predictive Models.
European School of Oncology &
Memorial Sloan-Kettering Cancer
Center, New York, New York
“QOL: Implications After Diagnosis - The
Unmeasurable Variable”
Oncology Congress, San Francisco, CA
“Comparative Effectiveness Research in
Prostate Cancer: Role of Observational
Studies”
Plenary Session, Society of Urological
Oncology Annual Meeting, Bethesda,
MD
“Patient-reported Outcomes in Prostate
Cancer”
Urology Visiting Professor, Memorial
Sloan Kettering Cancer Center, NY, NY
International Presentations
Years
Presentation
2008
“Patient-Reported Sexual Health after
Prostate Cancer Treatment”
Spanish Society of Sexual Medicine
Annual Conference, Madrid, Spain
2011
“Predicting Individualized Outcomes of Early
Stage Prostate Cancer”
Chilean Society of Urology, Santiago,
Chile
2012
Page 24
“Quality of Life and Satisfaction with Therapy
Amongst Prostate Cancer Survivors”
Societe International d’Urologie Annual
Meeting Plenary Session, Berlin,
Germany
“Predicting Quality of Life Effects of Prostate
Cancer Treatment”
Plenary Session, Annual Norwegian
Oncology Conference, Oslo, Norway
“New Molecular Targets for Prostate Cancer
Early Detection”
Genitourinary Section Meeting, Annual
Norwegian Oncology Conference, Oslo,
Norway
“Quality of Life and Satisfaction in Prostate
Cancer Care” and “Comparative Outcomes of
Robotic and Open Prostatectomy”
International Genito-urinary Cancer
Conference, Prague, Czech Republic
BIBLIOGRAPHY:
Report of Scholarship
Number of Citations (per Web of science - Science Citation Index) = 6,091
Hirsh Index = 32
I. Peer-reviewed Publications in Print or Other Media
1. Barth RJ, Mule JJ, Asher AL, Sanda MG, and SA Rosenberg. Identification of unique murine
tumor-associated antigens by tumor-infiltrating lymphocytes using tumor-specific secretion of
interferon-gamma and tumor necrosis factor. J IMMUNOL METH 1991;140: 269-79.
2. Sanda MG, Bolton E, Mule JJ, and SA Rosenberg. In vivo administration of recombinant
Macrophage-Colony Stimulating Factor induces macrophage-mediated antibody-dependent
cytotoxicity of tumor cells. J IMMUNOTHER 1992; 12:132-7.
3. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort R, de Smet MD,
Schwartzentruber DJ, White DE, Lotze MT, and SA Rosenberg. Intravenous administration of
recombinant human Macrophage Colony-Stimulating Factor to patients with metastatic cancer: A
phase I study. J CLIN ONCOLOGY 1992;10:1643-9.
4. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Dranoff G, Cohen LK, Pardoll DM,
Mulligan RC and Simons JW. Demonstration of a rational strategy for human prostate cancer gene
therapy. J UROL 1994; 151: 622-8.
5. Sanda MG, Beaty TH, Stutzman R, Childs B and Walsh PC. Genetic susceptibility of benign
prostatic hyperplasia. J UROL 1994;152:115-9.
6. Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim
HI, Levin RD, Pogrebniak HW, Balkissoon J, Fenton RM, DeBarge LR, Kaye J, Rosenberg SA and
Parkinson DR. Phase I trial of recombinant human M-CSF administered by continuous intravenous
infusion in patients with metastatic cancer. J NATL CANCER INST 1994; 86:39-45.
7. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN and Walsh PC. Concordance rates for
benign prostatic disease among twins suggest hereditary influence. UROLOGY 1994; 44: 646-50.
Page 25
8. Sanda MG and Simons JW. Gene therapy for urological cancer. UROLOGY 1994; 44:617-24.
9. Moore RG, DeMaree RD, Sanda MG and Kavoussi LR. Retroperitoneoscopy: effects of
insufflation media on surrounding tissue during balloon rupture. J ENDOUROL 1995; 9: 67-71,.
10. Sanda MG, Restifo NP, Walsh J, Pardoll DM, and Simons JW. Molecular characterization of
defective antigen processing in human prostate cancer. J NATL CANCER INST 1995; 87: 280-285
(see comments pp 241-3).
11. Carducci MA, Ayyagari SR, Sanda MG and Simons JW. Gene therapy for human prostate
cancer: translational research in the hormone refractory Dunning prostate model. CANCER 1995;
75: 2013-20.
12. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh
PC, and Simons JW. Selection of men at high risk for recurrence for experimental adjuvant therapy
following radical prostatectomy. UROLOGY 1995; 45: 831-8.
13. Sanda MG, Jeffs RD, and Gearhart JP. Evolution of outcomes with the ileal hydraulic valve
continent diversion: re-evaluation of the Benchekroun catheterizable stoma. WORLD J UROL
1996; 14:108-11.
14. Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, and
Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. UROLOGY
1996; 48:650-3.
15. Sanda MG, Doehring CB, Binkowitz B, Beaty TH , Partin AW, Stoner E, and Walsh PC. Clinical
and biological characteristics of familial benign prostatic hyperplasia. J UROL 1997; 157: 876-879.
16. Sanda MG. Biological principals and clinical development of prostate cancer gene therapy.
SEMINARS IN UROLOGIC ONCOLOGY 1997;15: 43-55.
17. Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Zeng Z, Greenberg NM, and
Sanda MG. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J
UROLOGY 1998; 160:1500-5.
18. Sanda MG, Smith D, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie
JE. Recombinant vaccinia-PSA can induce a prostate-specific immune response in androgenmodulated human prostate cancer. UROLOGY 1999; 53: 260-6.
19. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Imperiale M, Restifo NP, and Sanda MG.
Generation and characterization of a novel vaccinia vector for recombinant vaccine therapy of
tumors expressing SV40-T antigen. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999; 91:
169-75.
20. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA,
Goemann MA, Clift SM, Ando, DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW,
Carter HB, Piantadosi S, Marshall FF, and Nelson WG. Induction of immunity to prostate cancer
antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells
engineered to secret gm-csf using ex vivo gene transfer. CANCER RESEARCH 1999; 59: 51605168.
Page 26
21. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, and Sanda MG.
Early castration reduces prostatic carcinogenesis in transgenic mice. UROLOGY 1999; 54:11121119.
22. Charles LG, Xie YC, Restifo NP, Roessler B, and Sanda MG. Pre-clinical efficacy of
recombinant poxvirus immunization against Dunning rat prostate cancer in vivo. WORLD JOURNAL
OF UROLOGY 2000; 18:(2) 136-142.
23. Rubin MA, Bassily N, Sanda MG, Montie J, Strawderman MS, and Wojno KJ. The relationship
of greatest percent of biopsy core with cancer and perineural invasion in prostatic adenocarcinoma.
AM J SURG PATH 2000; 24(2) 183-189.
24. Francis T and Sanda MG. Prospects and limitations of gene therapy for prostate and bladder
cancers. CONTEMPORARY UROLOGY 2000; 12: 37-55.
25. Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, and Sanda MG. Bladder neck-sparing
modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate
cancer. UROLOGY 2000; 55(6): 904-8.
26. Hwang C and Sanda MG. Development of recombinant poxviruses for prostate cancer therapy.
CURRENT OPINION IN MOLECULAR THERAPEUTICS 2000; 1(4): 471-479.
27. Tchetgen MB, Faerber G, Sanda MG, and Montie JE. Collagen injection for the treatment of ISD
following cystectomy and orthotopic neobladder reconstruction in females. JOURNAL OF
UROLOGY 2000;163:212-214.
28. Rubin MA, Mucci N, Shah R, Sanda MG, Wei JT, and Montie JE. Benign prostatic glands on
surgical margins of radical prostatectomies: Frequency and associated risk factors. UROLOGY
2000; 56 (5): 721-725.
29. Wei JT, Dunn RL, Marcovich R, Montie, JE, and Sanda MG. Prospective assessment of patientreported urinary continence following radical prostatectomy.
JOURNAL OF UROLOGY
2000;164:744-748,.
30. Wei JT, Dunn RL, Litwin MS, Sandler HM, and Sanda MG. Development and validation of the
Expanded Prostate Caner Index Composite (EPIC) for comprehensive assessment of health-related
quality of life in men with prostate cancer. UROLOGY 2000; 56(6): 899-905.
31. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE,
Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC,
Partin AW, Carter HB, Piantadosi S, and Marshall FF. Cancer cells engineered to secrete GM-CSF
using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. CANCER
CHEMOTHERAPY & PHARMACOLOGY 2000; 46:S67-72.
32. Dawson LA, Litzenberg DW, Brock KK, Sanda MG, Sullivan M, Sandler HM, and Balter, JM. A
comparison of ventilatory prostate movement in four treatment positions. INT. J. RADIATION
ONCOLOGY BIOL. PHYS 2000; 48(2): 319-323.
33. Rubin MA, Mucci NR, Manley S, Cushenberry E, Strawderman M, Sanda MG, Montie JE, and
Bassily NH. Predictors of gleason pattern 4/5 prostate cancer on radical prostatectomy: Can high
grade tumor be predicted preoperatively? JOURNAL OF UROLOGY 2001;165(1): 114-118.
Page 27
34. Taj MM, Tawil RJ, Zeng Z, Hwang C, Sanda MG, and Wechsler DS. An Mxi1 adenovirus
suppresses growth of DU145 human prostate cancer cells. PROSTATE 2001; 47: 194-204.
35. Sandler H. Shipley WU. Gomella L. Pienta K. Bard RH. Bruner D. Clark R. DeSilvio M. Gaspar L.
Gillin M. Grignon D. Hammond E. Hanks G. Heydon KH. Kaufman DS. Lee WR. Michalski J. Mydlo
J. Pisansky T. Pollack A. Porterfield H. Rifkin M. Roach M 3rd. Sanda M. True L. Vijayakumar S.
Winter KA. Zeitman A. Radiation Therapy Oncology Group. Radiation Therapy Oncology Group.
Research Plan 2002-2006. Genitourinary Cancer Committee. INT J RADIAT ONCOL BIOL PHYS.
2001; 51(Suppl 2):28-38.
36. Rashid M, Sanda MG, Vallorosi C, Rios-Doria J, Rubin M, and Day M. Posttranslational
truncation and inactivation of human E-Cadherin distinguishes prostate cancer from matched normal
prostate. CANCER RESEARCH 2001; 61: 489-492.
37. Imperiale MJ, Pass HI, and Sanda MG. Prospects for an SV40 Vaccine. SEMINARS IN
CANCER BIOLOGY 2001; 11(1): 81-5.
38. Kielb SJ, Shah NL, Rubin MA, and Sanda MG. Functional p53 mutation as a molecular
determinant to paclitaxel and gemcitabine susceptibility in human bladder cancer. JOURNAL OF
UROLOGY 2001; 166(2): 482-487.
39. Kielb S, Dunn R, Rashid M, Murray S, Montie J, Sanda MG, and Wei J. Assessment of early
continence recovery following radical prostatectomy: Patient-reported symptoms and impairment.
JOURNAL OF UROLOGY 2001; 166(3): 958-961.
40. Nelson C, Rubin MA, Strawderman M, Montie JE, and Sanda MG. Pre-operative parameters for
predicting early prostate cancer recurrence following radical prostatectomy. UROLOGY 2002; 59:
740-746; discussion 745-6.
41. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, and Sanda MG. Neoadjuvant hormonal
therapy and older age are associated with adverse sexual HRQOL outcome after prostate
brachytherapy. UROLOGY 2002; 59(4):480-4.
42. Litzenberg DW, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock
KK and Balter JM: Daily prostate targeting using implanted radio-opaque markers. INT J RADIAT
ONCOL BIOL PHYS. 2002; 52: 699-703.
43. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, and Sanda
MG. A comprehensive comparison of health related quality of life following contemporary therapies
for localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY 2002; 20(2): 557-566.
44. Dash A, Sanda MG, Yu M, Taylor JMG, Fecko A, and Rubin MA. Prostate cancer involving the
bladder neck: recurrence-free survival and implications for AJCC staging modification UROLOGY
2002; 60(2):276-80.
45. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D,
Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is
involved in progression of prostate cancer. NATURE 2002; 419: 624 – 629.
46. Neeley CN, McDonagh KT, Overwijk WW, Restifo NP, and Sanda MG. Antigen-specific tumor
vaccine efficacy against prostate cancer with low class I MHC requires competent class II MHC. THE
PROSTATE 2002; 53:183-191.
Page 28
47. Rubin MA, Zhou M, Dhanasekaran S, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh
D, and Chinnaiyan AM. 
-Methylacyl-CoA Racemase: a highly specific and sensitive marker for
prostate cancer identified by DNA microarray analysis. JAMA 2002; 287:1662-1670.
48. Rao DS, Hyun TS, Mizukami IF, Rubin MA, Lucas PC, Sanda MG and Ross TS. Huntingtin
Interacting Protein 1: a tumor marker of prostate cancer progression. J CLINICAL INVESTIGATION
2002; 110: 351-360.
49. Nelson C and Sanda MG. Contemporary diagnosis and management of angiomyolipoma.
JOURNAL OF UROLOGY 2002; 168:1315-1325.
50. Tsien C, Griffith KA, Sandler HM, McLaughlin P, Sanda M, Montie J, Reddy S, Hayman JA Long
term results of 3D conformal adjuvant and salvage radiotherapy following radical prostatectomy.
UROLOGY, 2003; 62: 93-8.
51. Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG. Contemporary pre-operative
parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment
decisions. UROLOGIC ONCOLOGY: Seminars and Original Investigations. 2003; 21: 213-218.
52. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA and Day
ML. Cleavage of E-cadherin and the role of an 80kDa fragment in the metastatic progression of
prostate cancer. CLIN CANCER RES. 2003; 9: 6447-52.
53. Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, and W ei JT. Use of
quality indicators to evaluate localized prostate cancer care. CANCER 2003; 97:1428-35.
54. Rhodes D, Sanda MG, Otte AP, Chinnaiyan AM, and Rubin MA. Molecular markers for
predicting biochemical recurrence in men with clinically localized prostate caner: a multiplex analysis
using high-density tissue microarrays. JOURNAL OF THE NATIONAL CANCER INSTITUTE 2003;
95: 661-668.
55. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, and Sanda MG. Determinants of long-term sexual
HRQOL after radical prostatectomy measured by a validated instrument. JOURNAL OF UROLOGY
2003;169(4):1453-7.
56. Underwood W, Wei JT, Rubin MA, Resh J, Montie JE, and Sanda MG. Underwood W 3rd, Wei
J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free survival of African
Americans is similar to non-African Americans after adjustment for baseline cancer severity.
UROLOGIC ONCOLOGY 2004;22(1):20-4.
57. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D,
Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA
racemase and prostate cancer. J NATL CANCER INST. 2004 96(11): 834-43. Erratum in: J Natl
Cancer Inst. 2004 Jul 21;96(14):1112.
58. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy
impairs sexual outcome among younger men who undergo external beam radiotherapy for localized
prostate cancer. UROLOGY. 2004;63(5):946-50.
Page 29
59. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities
in the treatment of localized/regional prostate cancer. JOURNAL OF UROLOGY 2004;171(4):
1504-7.
60. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E,
Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM. Elevated alpha-methylacyl-CoA racemase
enzymatic activity in prostate cancer. AMERICAN JOURNAL OF PATHOLOGY 2004
Mar;164(3):787-93.
61. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda
MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in
prostate cancer progression. CANCER RESEARCH 2004; 64(3):825-9.
62. Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment
characteristics associated with homologous blood transfusion requirement during radical retropubic
prostatectomy: multivariate nomogram to assist patient counseling. UROLOGY 2004; 64(1):117-22.
63. Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after
prostatectomy, external radiation, or brachytherapy for early stage prostate cancer.
CURRENT UROLOGY REPORTS 2004; 5(3): 212-9.
64. Shah NL, Sanda M. Health-related quality of life in treatment for prostate cancer: looking beyond
survival. SUPPORT CANCER THER 2004 Jul 1;1(4):230-6. PubMed PMID: 18628147.
65. Miller, D, Sanda MG, Dunn RL et al. Long-term outcomes among localized prostate cancer
survivors: HRQOL changes 4 to 8 years following radical prostatectomy, external radiation and
brachytherapy. JOURNAL OF CLINICAL ONCOLOGY 2005; 23(12):2772-80.
66. Bradley SV, Oravecz-Wilson KJ, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A,
Corradetti MN, Chinnaiyan A, Sanda MG, and Ross TS. Serum Antibodies to Huntingtin Interacting
Protein-1: a new blood test for prostate cancer. CANCER RESEARCH 2005; 65(10):4126-33.
67. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta
KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures
in prostate cancer. N ENGL J MED 2005; 353(12):1224-35.
68. Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, Ogawa O, Fukuhara S,
Kakehi Y. [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index
Composite (EPIC)]. NIPPON HINYOKIKA GAKKAI ZASSHI. 2005 Nov; 96(7):657-69. Japanese.
PubMed PMID: 16363651.
69. Hofer, MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG,
Gschwend JE, and Rubin MA. Prognostic Factors in Lymph Node-Positive Prostate Cancer.
UROLOGY 2006; 6 (5):1016-21.
70. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel1 H, Sandler HM, McLaughlin PW, and Sanda
MG. Utilization of medications or devices for erectile dysfunction among long-term prostate cancer
treatment survivors: the potential influence of sexual motivation and/or indifference. UROLOGY
2006; 68(1):166-71.
Page 30
71. Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE, Wei JT.
Obesity adversely affects health related quality of life prior to and following radical retropubic
prostatectomy. J UROLOGY 2006; 176(1):257-61; discussion 261-2.
72. Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients'
expectations regarding health-related quality-of-life outcomes associated with prostate cancer
surgery or radiotherapy. UROLOGY 2006; 68(6):1224-9.
73. Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a
transgender woman 41 years after initiation of feminization. JAMA 2006; 296(19):2316-7.
74. Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC,
Sanda MG, Kershaw T. Living with prostate cancer: patients' and spouses' psychosocial status and
quality of life. J CLIN ONCOL 2007; 25(27):4171-7.
75. Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using
magnetic resonance imaging for solid components in cystic renal neoplasms. UROLOGY
2008;71(1):47-51.
76. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A
safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DESIGN,
DEVELOPMENT AND THERAPY 2008; 2:17–24 (open access).
77. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.[2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute
Early Detection Research Network Validation Study. J UROLOGY 2008 180(2):539-43
78. Mosquera JM, Perner S, Genega E, Sanda MG, Hofer M, Mertz K, Paris P, Simko J, Bismar T,
Ayala G, Shah R, Loda M, Rubin M. Characterization of TMPRSS2-ERG Fusion High-grade
Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. CLINICAL CANCER
RESEARCH 2008; 14(11):3380-5.
79. Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Partially
circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
PROSTATE 2008; 68(7):715-27.
80. Hollenbeck BK, Dunn RL, Wolf JS Jr, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE,
Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for
measuring quality of life after surgery. QUAL LIFE RES 2008 17(6): 915-26.
81. Hu J, Hevelone N, Earle CC, Sanda MG, Lipsitz SR. Patterns of care for radical prostatectomy
in the United States from 2003-2005. J UROLOGY 2008; 180(5):1969-74
82. Haram KM, Peltier HJ, Lu B, Bhasin M, Out HH, Choy B, Regan M, Libermann TA, Latham GJ,
Sanda MG,* Arredouani MS.* Gene expression profile of mouse prostate tumors reveals
dysregulation in major biological processes and identifies potential murine targets for preclinical
development of human prostate cancer therapy. PROSTATE, 2008; 68(14):1517-30.
83. Kershaw TS, Mood DW, Newth G, Ronis DL, Sanda MG, Vaishampayan U, Northouse LL.
Longitudinal Analysis of a Model to Predict Quality of Life in Prostate Cancer Patients and their
Spouses. ANN BEHAV MED 2008 36 (2):117-128. Epub 2008 Sep 16.
Page 31
84. Dandapani S and Sanda MG. Measuring health-related quality of life consequences from
primary treatment for early stage prostate cancer. SEM RAD ONC 2008; 18(1):67-72.
85. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda MG, Vaishampayan U,
Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II Trial of Paclitaxel, Carboplatin, and
Gemcitabine in patients with Locally Advanced Carcinoma of the Bladder. J UROLOGY 2008
Dec;180(6):2384-8; discussion 2388. Epub 2008 Oct 18. PMID: 18930256
86. Ramachandran N, Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, Pacek M,
Wong J, Eljanne M, Sanda MG, Hu YH, Logvinenko T, LaBaer J. Tracking humoral responses using
self assembling protein microarrays. PROTEOMICS CLINICAL APPLICATIONS 2008 Oct; 2(1011): 1518-1527.
87. Tseng-Rogenski S, Arredouani M, Neeley Y, Lu B, Chinnaiyan A, Sanda MG. Fas-mediated T
cell deletion protentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
CANCER IMMUNOLOGY, AND IMMUNOTHERAPY 2008; 57(9):1357-65.
88. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK,
Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D,
Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer
survivors. NEW ENGLAND JOURNAL OF MEDICINE 2008; 358(12):1250-61.
89. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara
L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma
Collection: Early Detection Research Network Consensus Statement. JOURNAL OF PROTEOME
RESEARCH, 2009; 8 (1): 113-117.
90. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, and Sanda
MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DES DEVEL
THER. 2009; 2:17-24. PubMed PMID: 19920890.
91. Sanda MG and Kaplan I. Clinical Crossroads: Management of Early Stage Prostate Cancer
JAMA 2009; 301(20):2141-51. Epub 2009 May 5. PMID: 19417179.
92. Shappley WV III, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG,* and Chan JM*
A prospective study of determinants and outcomes of deferred treatment or watchful waiting among
men with prostate cancer in a nationwide cohort. J CLIN ONCOL 2009 Oct 20;27(30):4980-5. Epub
2009 Aug 31. PubMed PMID: 19720918.
93. Mosquera JM, Mehra R, Regan MM, Perner S, Genega MG, Bueti G, Shah RB, Gaston S,
Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA,* and Sanda
MG.* Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy
in the United States. CLINICAL CANCER RESEARCH, 2009; 15(14):4706-11. Epub 2009 Jul 7.
PMID: 19584163
94. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V,
Rubin MA, Libermann TA, Sanda MG. Identification of the Transcription Factor Single-Minded
Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. CLIN
CANCER RES. 2009 Sep 15;15(18):5794-802. Epub 2009 Sep 8. PMID: 19737960.
95. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M,
Sanda MG. Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens
Page 32
by a Novel Assay Using Branched DNA. UROLOGY Nov; 74(5):1156-61. Epub 2009 Aug 3. PubMed
PMID: 19647299; PubMed Central PMCID: PMC2784207.
96. Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M,
Thompson IM, Sanda MG. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer
Prevention Trial Calculator for Predicting Prostate Cancer Detection. JOURNAL OF UROLOGY,
2009 Dec;182(6):2653-8. PubMed PMID: 19836788.
97. Sandler HM, Liu P, Dunn RL, Khan DC, Tropper SE, Sanda MG, and Mantz CA. Reduction in
patient-reported morbidity in prostate cancer patients treated with 81 gy IMRT using reduced PTV
margins and electromagnetic tracking: assessing the impact of margin reduction (AIM) study.
UROLOGY, 2010 May;75(5):1004-8. Epub 2010 Feb 13. PubMed PMID: 20153881.
98. Arredouani MS, Tseng-Rogenski S, Hollenbeck BK, Defeo-Jones D, Hwang C, and Sanda MG.
Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self antigen in
transgenic mice. PROSTATE, 2010 Jun 15;70(9):1002-11. PubMed PMID: 20209643.
99. Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll
PR, Zietman AL. CaP calculator: An online decision support tool for clinically localized prostate
cancer. BRIT J UROLOGY INTL, 2010 May; 105(10):1417-22. Epub 2010 Mar 15. PubMed PMID:
20346051.
100. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S,
Thompson IM, Wei JT, Zhang Z, and Chan DW. A prospective, multicenter, NCI EDRN study of [2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness.
CANCER EPIDEMIOL BIOMARKERS PREV. 2010 May 19(5):1193-2000. PubMed PMID:
20447916; PubMed Central PMCID: PMC2867076.
101. Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE; PROSTQA Study Group. The
experiences of unpartnered men with prostate cancer: a qualitative analysis. J CANCER SURVIV.
2011 Jun;5(2):132-41. doi: 10.1007/s11764-010-0157-3. Epub 2010 Nov 28. PubMed PMID:
21113818.
102. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley
MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin12 with alpha-galactosylceramide. PLOS ONE. 2010 Jun 25;5(6):e11311. PubMed PMID: 20593019;
PubMed Central PMCID: PMC2892484.
103. Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich
CP. Comparison of validated instruments measuring sexual function in men. UROLOGY. 2010
Aug;76(2):380-6. Epub 2010 Jun 22. PubMed PMID: 20573377.
104. Kazer MW, Bailey DE, Sanda MG, Colberg, J, Kelly, WK. Internet Uncertainty Management
Intervention for Older Men undergoing Active Surveillance for Prostate Cancer. ONCOLOGY
NURSING FORUM. 2011 Sep;38(5):561-8. PubMed PMID: 21875843.
105. Szymanski KM, Wei JT, Dunn RL, and Sanda MG. Development and validation of an
abbreviated version of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) for
measuring Health-Related Quality of Life among prostate cancer survivors. UROLOGY, 2010 Mar
27. [Epub ahead of print] PubMed PMID: 20350762.
Page 33
106. Bhatt RS, Werner L, Regan MM, Yannucci J, Wang HY, Rosen S, Genega E, Morrissey ME,
Duggan S, Vazquez C, Sanda MG, DeWolf W, Balk S, Yuan X, Bubley GJ. Possible risk factors
associated with relapse in patients treated with neoadjuvant chemohormonal therapy for high risk
prostate cancer. OPEN PROSTATE CA JOURNAL, accepted for publication.
107. Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W.
Racial/Ethnic Differences in Receipt of Pelvic Lymph Node Dissection among Men with
Localized/Regional Prostate Cancer. CANCER, Oct 15 2011 Volume: 117(20): 4651-4658.
108. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS,
Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RHN, Mizrahi
IA. A Multi-Center Study of [-2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and
Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. J UROLOGY, 2011
May;185(5):1650-5. Epub 2011 Mar 17. PMID: 21419439.
109. Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda
MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care
administered via paper or via the Internet. ANN ONCOL. 2011 Mar; 22(3):723-9. Epub 2010 Aug 17.
PMID: 20716625.
110. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J,
Tomlins SA, Wei JT, Chinnaiyan AM,* Rubin MA,* Sanda MG.* Combining urinary detection of
TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol.
2011 May 19. [Epub ahead of print] PubMed PMID: 21600800.
111. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R,
Wagner AA, DeWolf WS, Bubley GJ, Funches R, Aronovitz JA, Wei JT,* and Sanda MG.* Expanded
Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): Development and Validation of a
Practical Health-Related Quality of Life Instrument for Use in the Routine Clinical Care of Prostate
Cancer Patients. JOURNAL OF UROLOGY, 2011 Sep;186(3):865-72. Epub 2011 Jul 23. PubMed
PMID: 21788038.
112. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge
P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG,
Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers
S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG Fusion
Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. SCIENCE TRANSL
MED. 2011 Aug 3; 3(94):94ra72. PubMed PMID: 21813756.
113. Kasperzyk JL, Shappley WV 3rd, Kenfield SA, Mucci LA, Kurth T, Ma J, Stampfer
MJ, Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the
Physicians' Health Study. J Urol. 2011 Nov;186(5):1862-7. Epub 2011 Sep 23. PubMed PMID:
21944095.
114. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L,
Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID,
Wood DP, Ciezki J, Dunn RL, Carroll PR, and Sanda MG. Prediction of Erectile Function Following
Treatment for Prostate Cancer. JAMA, 2011 Sep 21; 306(11):1205-14. PMID:21934053.
115. Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG,
Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial
Page 34
resolution dynamic contrast-enhanced 3-T MRI. EUR RADIOL. 2012 Jun 3. [Epub ahead of print]
116. Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan
J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer.
BIOM J. 2012 Jan;54(1):127-42. doi: 10.1002/bimj.201100062. Epub 2011 Nov 17. PubMed PMID:
22095849.
117. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL,
Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff
PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG Rearrangement,
ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis. CANCER
EPIDEMIOL BIOMARKERS PREV. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22736790.
118. Kim SB, Williams SB, Cheng SC, Sanda MG, Wagner AA. Evaluation of Patient-reported
Quality-of-life Outcomes After Renal Surgery. UROLOGY. 2012 Jun;79(6):1268-73. Epub 2012 Apr
28. PubMed PMID: 22542421; PubMed Central PMCID: PMC3367127.
119. Harden JK, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, Northouse LL; PROSTQA
Consortium Study Group. Partners' Long-term Appraisal of Their Caregiving Experience, Marital
Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment.
CANCER NURS. 2012 Jun 21. [Epub ahead of print] PubMed PMID: 22728952.
120. Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H,
Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM,
Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT,
Scherr DS, Sanda MG, Bartsch G, Lee C, Klocker H, Rubin MA. Identification of functionally active,
low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
PROC NATL ACAD SCI U S A. 2012 Apr 24;109(17):6686-91. Epub 2012 Apr 10. PubMed PMID:
22496589; PubMed Central PMCID: PMC3340033.
121. Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in
prostate cancer. PLOS ONE. 2011;6(12):e28837. Epub 2011 Dec 9. PubMed PMID: 22174909;
PubMed Central PMCID: PMC3235151.
122. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM,
Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection
Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the
Prostate Cancer Prevention Trial. CANCER. 2012 May 15;118 (10):2651-8. doi:
10.1002/cncr.26396. Epub 2011 Oct 17. PubMed PMID: 22006057.
* Designates shared senior authorship
Page 35
II. Chapters, Editorials, Proceedings, or non-Peer Reviewed Publications/Print Materials
1. Lotze MT, Custer MC, Kawakami Y, Stotter H, Rubin JT, Bolton ES, Guedez L, Sanda MG. T cell
growth factors and the expansion of lymphoid cells with antitumor activity in vitro and in vivo.
CELLULAR IMMUNITY AND IMMUNOTHERAPY OF CANCER; 1990 pp 91-104
2. Sanda MG, Pierson RP, Smith C, Reemtsma K, and E Rose. Serum dipeptidyl-peptidase IV in
cardiac transplant recipients. TRANSPLANTATION PROC 1989; 21:2525-6.
3. Sanda MG and Marshall FF. Endoscopic reconstruction of traumatic posterior urethral
disruptions. In: Traumatic and Reconstructive Urology, McAninch JW, ed. WB Saunders Co, 1996.
4. Sanda MG. Genetic considerations and gene therapy. In: Urological Oncology, Oesterling JE
and Richie JP, eds. WB Saunders Co, 1997.
5. Sanda MG and Montie JE. Prostate cancer - postoperative care. In: Surgery of the Prostate,
Resnick MI and Thompson I, eds. Churchill Livingstone, 1997.
6. Sanda MG. Consensus parameters define a PSA recurrence after radiation therapy. AUA
NEWS, January, 1998
7. Sanda MG. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the
treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis –
Comment. UROLOGY Volume: 51 Issue: 6; 890-890, 1998.
8. Pienta KJ, Sandler H, and Sanda MG. Prostate cancer. In: Cancer Management: A
Multidisciplinary Approach (Second edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds.
PRR, 1999.
9. Rashid M and Sanda MG. Gene therapy: practice and promise. In: The Management of
Prostate Cancer, Klein EA, ed., Humana Press, Inc., 1999.
10. Pienta KJ, Sandler H, Kielb SJ, and Sanda MG. Prostate cancer. In: Cancer Management: A
Multidisciplinary Approach (Third edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds.
PRR, 2000.
11. Francis T and Sanda MG. Prospects and limitations of gene therapy for prostate and bladder
cancers. CONTEMPORARY UROLOGY 2000; 12: 37-55.
12. Hollenbeck BK, Montie JE, and Sanda MG. Management of high risk prostate cancer. In:
Prostate Cancer, Kantoff P and D’Amico A, ed., 2001.
13. Pienta KJ, Sandler H, Sanda MG, and Hollenbeck BK. Prostate cancer. In: Cancer
Management: A Multidisciplinary Approach (Fourth edition), Pazdur R, Coia LR, Hoskins WJ, and
Wagman LD, eds. PRR, 2001.
14. Sanda MG. AUA Take home message - prostate cancer. Urology Times Vol. 30, No. 8; 2002
(August). pages 1, 12.
15. Shah N, and Sanda MG. “Quality of Life Affecting Treatment Decisions for Prostate Cancer.”
Cancernews.com, May 2002.
Page 36
16. Pienta KJ, Sandler H, Shah N, and Sanda MG. Prostate cancer. In: Cancer Management: A
Multidisciplinary Approach (Fifth edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds.
PRR, 2002.
17. Hafez KS and Sanda MG. Contemporary clinical trials of prostate cancer immunotherapy. In:
Disorders of the Prostate: Advances in Basic Mechanisms and the Implications for Clinical
Management. Habib FK and Briley M, eds. Martin Dinitz Publishing, 2004.
18. Sanda MG and Rodriguez R. Gene therapy for urologic cancer: basic principles, prospects, and
limitations. Chapter 2 (pp 18-38) In: Urologic Oncology, JP Richie and AP D’Amico, eds. ElsevierSaunders, 2005.
19. George, AK, Sanda MG, Measuring Patient Satisfaction. Chapter 14 (pp 253-262) Clinical
Research Methods for Surgeons. Humana Press, Inc., 2006
20. Sanda MG. “The AUA’s Topical Urology Audio Series.” Oakstone Medical Publishing, LLC,
August 2006.
21. Sanda MG. Bringing prostate cancer quality of life research back to the bedside: Translating
numbers into a format that patients can understand – Commentary. JOURNAL OF UROLOGY
176(4); 1563-1564 DOI: 10.1016/j.juro.2006.06.164; 2006
22. Sanda MG, Wagner, AA, Su, LM. Retropubic, Laparoscopic, and Robotic-Assisted Radical
Prostatectomy. Chapter 157 (pp 1742-1753). Mastery of Surgery, 5th edition, Vol 2. Lippincott
Williams & Wilkins 2007
23. Loughlin K, Morgentaler A, Sanda M and Garnick M. Harvard Experts Discuss Benign Prostatic
Hyperplasia Drug Treatment. Perspectives on Prostate Disease Winter 2007 Vol 1 No 1
24. Sanda MG. Editorial Comment re: Quality of life after multi-modality therapy for prostate cancer.
J Urol. 2008 Oct 16; 180 (6): 2422.
25. Sanda MG, Kasibhatla M. Is androgen suppression therapy associated with early onset of fatal
myocardial infarction? NAT CLIN PRACT UROL 2008; 5(4):184-5.
26. McDermott DW and Sanda MG. Health-related quality-of-life effects of watchful waiting reevaluated in SPCG-4. NATURE CLINICAL PRACTICE UROLOGY, March 2009 6 (3): 124-125.
27. Sanda MG. Live longer but not better ... yet. LANCET ONCOLOGY April 2009; 10 (4): 313-314
28. Sanda MG. Editorial comment. Nerve sparing during radical prostatectomy is associated with
better recovery of urinary continence. UROLOGY. 2009 Jun;73(6):1340-1; author reply 1341.
29. Sanda, MG Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index
and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy Editorial Comment JOURNAL OF UROLOGY JUL 2009 182; 228.
30. Aronovitz JA, Sanda MG. Further perspectives on treating localized prostate cancer.
ONCOLOGY (Williston Park). 2009 Oct;23(11):964, 966. PubMed PMID: 19947348.
Page 37
31. Sanda MG. Editorial comment. Acute lower urinary tract symptoms after prostate
brachytherapy with cesium-131. Urology. 2010 Nov;76(5):1148; author reply 1148-9.
32. Sanda MG. Urinary obstructive problems exposed but hormonal health-related quality-of-life
concerns eschewed in prostate cancer quality-of-life study. J Clin Oncol. 2010 Nov 1;28(31):4667-8.
Epub 2010 Oct 4. PubMed PMID: 20921452..
33. Chang P, Alemozaffar A, and Sanda MG. Clinical Implications of Measuring Quality-of-Life in
Early Stage Prostate Cancer. In Management of Prostate Cancer, E. Klein, Ed., 3rd edition;
Scheduled to print.
34. Eleni Efstathiou E, Smith MR, Sartor AO, Drake CG, Rathkopf D, DePinho R, Efstathiou JA,
Sanda MG, Feldman AS, and Chabner BA. Prostate Cancer – Progress and Promise, Part I, The
Oncologist, In Press.
35. Alemozaffar M and Sanda MG. Quality of Life after Treatment for Early Stage Prostate Cancer.
In Comprehensive Textbook of Genitourinary Oncology; Vogelzang NJ, Scardino PT, Zelefsky MJ,
Linehan WM, eds. Lippincott Williams & Wilkins. 2012.
36. Wagner A and Sanda MG. Retropubic, Laparoscopic, and Robotic-Assisted Radical
Prostatectomy, In Mastery of Surgery, 6th ed., J. Fischer, Ed. Lippincott Williams & Wilkins. In Press.

Martin George Sanda, MD

Transcription

Similar documents